Fundraising FoxjCyte
Newport Beach, US · Delaware corporation
Find your way into jCyte
Sign up to see every warm intro you have to jCyte
- Paths you didn't know you had: your email and LinkedIn already hold routes to the jCyte team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
jCyte is a clinical-stage biotechnology company developing jCell, an investigational cell-based therapy for retinitis pigmentosa and other inherited retinal and blinding diseases. It is advancing multiple drug development programs targeting degenerative retinal disorders and optic nerve conditions to preserve and restore vision.
Founders & leadership
HK
Henry KlassenCo-founder
JY
Jing YangCo-founder
PB
Paul BresgeExecutive
TO
Terry O'NealExecutive
Reported raises · per SEC filings
Form D private placements$3.9M disclosed across 1 round · 2019
▶$3.9MraisedApr 2019 · 53 investors · OtherRule 506(b)
▶$3.9MraisedApr 2019 · 53 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Henry KlassenDirector
- Paul BresgeExecutive Officer
- Terry O'NealExecutive Officer, Director
- Jing YangDirector
- Offering amount
- $6M
- Amount sold
- $3.9M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Incyte CorporationIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
シンクサイトThinkCyte develops diagnostic devices and cellular analysis platforms using imaging flow cytometry and microfluidics technology. The company serves research institutions, clinical laboratories, and biopharmaceutical companies in the life sciences and diagnostic tools sector.
Companies working in the same space as jCyte.
Frequently asked questions
- What does jCyte do?
- jCyte is a clinical-stage biotechnology company developing jCell, an investigational cell-based therapy for retinitis pigmentosa and other inherited retinal and blinding diseases. It is advancing multiple drug development programs targeting degenerative retinal disorders and optic nerve conditions to preserve and restore vision.
- Who founded jCyte?
- jCyte was founded by Henry Klassen, Jing Yang.
- How much funding has jCyte raised?
- jCyte has disclosed $3.9M raised across 1 round.
- Where is jCyte headquartered?
- jCyte is headquartered in Newport Beach, US.